FDA Extends Review Period for Praxis Drug Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: Newsfilter
- Review Period Extended: The FDA has extended the PDUFA date for Praxis Precision Medicines' relutrigine NDA from September 27, 2026, to December 27, 2026, allowing an additional three months for thorough review, indicating the FDA's significant attention to the drug.
- Supplementary Data Analysis: This extension follows Praxis's submission of additional sensitivity analyses, which the FDA classified as a 'major amendment,' thereby enhancing the credibility of the application based on existing clinical data.
- No New Clinical Studies Required: The FDA did not request new clinical studies nor raised any safety or manufacturing concerns, suggesting that the existing data is sufficient to support the review process, and Praxis remains confident in the market potential of relutrigine.
- Urgent Patient Need: Praxis is actively preparing to deliver relutrigine to the patient community suffering from SCN2A and SCN8A developmental epileptic encephalopathies, emphasizing the drug's potential to address significant unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 327.790
Low
95.00
Averages
456.71
High
843.00
Current: 327.790
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is an integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company's product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-080, Elsunersen, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Extends Review Period for Praxis Drug Application
- Review Period Extended: The FDA has extended the PDUFA date for Praxis Precision Medicines' relutrigine NDA from September 27, 2026, to December 27, 2026, allowing an additional three months for thorough review, indicating the FDA's significant attention to the drug.
- Supplementary Data Analysis: This extension follows Praxis's submission of additional sensitivity analyses, which the FDA classified as a 'major amendment,' thereby enhancing the credibility of the application based on existing clinical data.
- No New Clinical Studies Required: The FDA did not request new clinical studies nor raised any safety or manufacturing concerns, suggesting that the existing data is sufficient to support the review process, and Praxis remains confident in the market potential of relutrigine.
- Urgent Patient Need: Praxis is actively preparing to deliver relutrigine to the patient community suffering from SCN2A and SCN8A developmental epileptic encephalopathies, emphasizing the drug's potential to address significant unmet medical needs.
See More
FDA Extends Review Period for Praxis Drug Application
- Review Period Extended: The FDA has extended the review period for Praxis Precision Medicines' application for relutrigine by three months to December 27, due to the submission of additional sensitivity analyses, which the agency considers a 'major amendment.'
- No New Studies Required: The extension does not require new studies from Praxis, nor were any safety or manufacturing issues mentioned, indicating the FDA's focus on existing data, which may facilitate a faster approval process.
- Positive Market Reaction: Praxis's performance under FDA Breakthrough Therapy status has garnered market attention, particularly regarding its potential treatment for SCN2A and SCN8A developmental epileptic encephalopathies, which may boost investor confidence.
- Optimistic Future Outlook: With other drugs like Ulixacaltamide expected to receive PDUFA in early 2027, Praxis demonstrates ongoing innovation and market potential in the neuroscience sector.
See More
Praxis Receives FDA Breakthrough Therapy Designation for Elsunersen
- FDA Breakthrough Designation: Praxis Precision Medicines' Elsunersen has received Breakthrough Therapy Designation from the U.S. FDA for treating seizures associated with SCN2A Developmental and Epileptic Encephalopathy, based on promising early clinical results, which is expected to expedite the therapy's development timeline.
- Clinical Data Support: Findings from Part A of the EMBRAVE study indicate that patients treated with Elsunersen experienced a 77% reduction in monthly seizure frequency compared to the sham control group, with improvements sustained for up to one year in the open-label extension, demonstrating significant efficacy of the therapy.
- Ongoing Registrational Study: Praxis is continuing enrollment in its EMBRAVE3 registrational trial, which follows a streamlined development pathway agreed upon with the FDA, planning to enroll approximately 30 patients, with all participants receiving Elsunersen for an initial 24-week treatment period followed by a 24-week extension.
- Multiple Regulatory Designations: Elsunersen has received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease Designations in the U.S., as well as Orphan Drug and PRIME status in Europe, reinforcing its potential to address a significant unmet medical need.
See More
Praxis Receives FDA Breakthrough Therapy Designation for Seizures
- Breakthrough Therapy Designation: The US FDA has awarded Praxis Precision Medicines (PRAX) Breakthrough Therapy Designation for its seizure drug forelsunersen, marking a significant advancement in the treatment of SCN2A developmental and epileptic encephalopathy, which is expected to expedite the clinical development process.
- Multiple Drug Status: The asset has already received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from the FDA, indicating its potential in treating rare diseases, which may attract more investor interest and enhance the company's market value.
- Clinical Trial Progress: The pivotal study EMBRAVE3 is currently enrolling patients, demonstrating Praxis's proactive efforts in advancing the clinical trial of the drug, with successful completion potentially leading to significant commercial opportunities for the company.
- Market Outlook Analysis: Praxis showcased its product line at recent healthcare conferences, and despite facing high market expectations for Essential Tremor, its stock price has declined due to setbacks in seizure therapy trials, reflecting a cautious market sentiment regarding its future prospects.
See More
Praxis Receives Breakthrough Therapy Designation for Elsunersen
- Clinical Trial Results: In the EMBRAVE Part A trial, elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), indicating its potential as the first disease-modifying therapy for SCN2A-DEE.
- FDA Certification Impact: The Breakthrough Therapy Designation accelerates the development and regulatory review of elsunersen, enhancing Praxis's market position in the CNS field while providing patients with quicker access to treatment options that address unmet medical needs.
- Significant Patient Benefits: In the trial, 71% of patients achieved over a 50% reduction in seizures, and 57% experienced at least a 28-day seizure-free period during the six-month treatment, highlighting the drug's substantial impact on improving patient quality of life.
- Future Research Directions: The EMBRAVE3 study will adopt a single-arm design, aiming to enroll approximately 30 patients to further validate the efficacy and safety of elsunersen, laying the groundwork for Praxis's subsequent product development and market introduction.
See More
RBC Capital Markets Initiates Praxis Precision with Outperform Rating
- Positive Market Outlook: RBC Capital Markets has initiated coverage on Praxis Precision Markets with an outperform rating, citing a recent pullback as a good entry point, and they expect a transformative next six months with a price target of $449, representing a 66% upside from the June 17 close.
- Significant Sales Potential: Analyst Leonid Timashev highlighted that ulixacaltamide has a sales potential exceeding $4.3 billion for essential tremor, acknowledging regulatory risks but noting strong physician willingness to prescribe, indicating a large unmet need in the market.
- Long-term Revenue Prospects: Timashev also mentioned that Praxis could achieve over $7.8 billion in revenue by 2035, which is attractive to investors and suggests strong growth potential in future market competition.
- New Drug Development Opportunities: For genetically driven epilepsy, Timashev sees a high probability of success for relutrigine, while elsunersen could contribute an additional $200 million for the most severe patients, although feedback indicates not all families would opt for this antisense oligonucleotide treatment.
See More
FDA Extends Review Period for Praxis Drug Application
- Review Period Extended: The FDA has extended the PDUFA date for Praxis Precision Medicines' relutrigine NDA from September 27, 2026, to December 27, 2026, allowing an additional three months for thorough review, indicating the FDA's significant attention to the drug.
- Supplementary Data Analysis: This extension follows Praxis's submission of additional sensitivity analyses, which the FDA classified as a 'major amendment,' thereby enhancing the credibility of the application based on existing clinical data.
- No New Clinical Studies Required: The FDA did not request new clinical studies nor raised any safety or manufacturing concerns, suggesting that the existing data is sufficient to support the review process, and Praxis remains confident in the market potential of relutrigine.
- Urgent Patient Need: Praxis is actively preparing to deliver relutrigine to the patient community suffering from SCN2A and SCN8A developmental epileptic encephalopathies, emphasizing the drug's potential to address significant unmet medical needs.
See More
FDA Extends Review Period for Praxis Drug Application
- Review Period Extended: The FDA has extended the review period for Praxis Precision Medicines' application for relutrigine by three months to December 27, due to the submission of additional sensitivity analyses, which the agency considers a 'major amendment.'
- No New Studies Required: The extension does not require new studies from Praxis, nor were any safety or manufacturing issues mentioned, indicating the FDA's focus on existing data, which may facilitate a faster approval process.
- Positive Market Reaction: Praxis's performance under FDA Breakthrough Therapy status has garnered market attention, particularly regarding its potential treatment for SCN2A and SCN8A developmental epileptic encephalopathies, which may boost investor confidence.
- Optimistic Future Outlook: With other drugs like Ulixacaltamide expected to receive PDUFA in early 2027, Praxis demonstrates ongoing innovation and market potential in the neuroscience sector.
See More
Praxis Receives FDA Breakthrough Therapy Designation for Elsunersen
- FDA Breakthrough Designation: Praxis Precision Medicines' Elsunersen has received Breakthrough Therapy Designation from the U.S. FDA for treating seizures associated with SCN2A Developmental and Epileptic Encephalopathy, based on promising early clinical results, which is expected to expedite the therapy's development timeline.
- Clinical Data Support: Findings from Part A of the EMBRAVE study indicate that patients treated with Elsunersen experienced a 77% reduction in monthly seizure frequency compared to the sham control group, with improvements sustained for up to one year in the open-label extension, demonstrating significant efficacy of the therapy.
- Ongoing Registrational Study: Praxis is continuing enrollment in its EMBRAVE3 registrational trial, which follows a streamlined development pathway agreed upon with the FDA, planning to enroll approximately 30 patients, with all participants receiving Elsunersen for an initial 24-week treatment period followed by a 24-week extension.
- Multiple Regulatory Designations: Elsunersen has received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease Designations in the U.S., as well as Orphan Drug and PRIME status in Europe, reinforcing its potential to address a significant unmet medical need.
See More
Praxis Receives FDA Breakthrough Therapy Designation for Seizures
- Breakthrough Therapy Designation: The US FDA has awarded Praxis Precision Medicines (PRAX) Breakthrough Therapy Designation for its seizure drug forelsunersen, marking a significant advancement in the treatment of SCN2A developmental and epileptic encephalopathy, which is expected to expedite the clinical development process.
- Multiple Drug Status: The asset has already received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from the FDA, indicating its potential in treating rare diseases, which may attract more investor interest and enhance the company's market value.
- Clinical Trial Progress: The pivotal study EMBRAVE3 is currently enrolling patients, demonstrating Praxis's proactive efforts in advancing the clinical trial of the drug, with successful completion potentially leading to significant commercial opportunities for the company.
- Market Outlook Analysis: Praxis showcased its product line at recent healthcare conferences, and despite facing high market expectations for Essential Tremor, its stock price has declined due to setbacks in seizure therapy trials, reflecting a cautious market sentiment regarding its future prospects.
See More
Praxis Receives Breakthrough Therapy Designation for Elsunersen
- Clinical Trial Results: In the EMBRAVE Part A trial, elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), indicating its potential as the first disease-modifying therapy for SCN2A-DEE.
- FDA Certification Impact: The Breakthrough Therapy Designation accelerates the development and regulatory review of elsunersen, enhancing Praxis's market position in the CNS field while providing patients with quicker access to treatment options that address unmet medical needs.
- Significant Patient Benefits: In the trial, 71% of patients achieved over a 50% reduction in seizures, and 57% experienced at least a 28-day seizure-free period during the six-month treatment, highlighting the drug's substantial impact on improving patient quality of life.
- Future Research Directions: The EMBRAVE3 study will adopt a single-arm design, aiming to enroll approximately 30 patients to further validate the efficacy and safety of elsunersen, laying the groundwork for Praxis's subsequent product development and market introduction.
See More
RBC Capital Markets Initiates Praxis Precision with Outperform Rating
- Positive Market Outlook: RBC Capital Markets has initiated coverage on Praxis Precision Markets with an outperform rating, citing a recent pullback as a good entry point, and they expect a transformative next six months with a price target of $449, representing a 66% upside from the June 17 close.
- Significant Sales Potential: Analyst Leonid Timashev highlighted that ulixacaltamide has a sales potential exceeding $4.3 billion for essential tremor, acknowledging regulatory risks but noting strong physician willingness to prescribe, indicating a large unmet need in the market.
- Long-term Revenue Prospects: Timashev also mentioned that Praxis could achieve over $7.8 billion in revenue by 2035, which is attractive to investors and suggests strong growth potential in future market competition.
- New Drug Development Opportunities: For genetically driven epilepsy, Timashev sees a high probability of success for relutrigine, while elsunersen could contribute an additional $200 million for the most severe patients, although feedback indicates not all families would opt for this antisense oligonucleotide treatment.
See More
